Aspen’s supplementary response to the South African Competition Commission Announcement ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (“Aspen Holdings”) Registration number 1985/0002935/06 Share code: APN ISIN: ZAE000066692 and its subsidiaries (collectively “Aspen” or “the Aspen Group”) ASPEN’S SUPPLEMENTARY RESPONSE TO THE SOUTH AFRICAN COMPETITION COMMISSION ANNOUNCEMENT Shareholders are referred to the SENS announcement released by Aspen on 13 June 2017 wherein it was confirmed that: - Aspen had noted the announcement made by the South African Competition Commission (“the Commission”) on 13 June 2017 that it will be investigating Aspen for suspected abuse of dominance in respect of the provision of cancer medication in South Africa; - pharmaceutical prices in South Africa are approved by the South African Department of Health in terms of the Single Exit Price (“SEP”) regulatory framework which establishes a universal fixed price for each pharmaceutical product; and - Aspen has not increased pricing of its products outside of this regulatory framework and has clearly demonstrated its commitment to providing quality medicines affordably over many years. The supply of the oncology products in question is no exception. As further clarification, Aspen confirms that it has, to date, not had any engagement with the Commission on the matters contained in the Commission’s announcement of 13 June 2017 and welcomes the opportunity to meet and clarify the following key issues on the products listed by the Commission in its announcement: - these products are all post-patent and have been for some time now; - there are no obvious barriers precluding generic entry for these products. Invariably in situations like these, the lack of generic entry is either attributable to the sub-economical pricing of the branded products and/or an unattractive market size; and - despite the lack of generic competition on these products, Aspen reiterates and emphasises that it has never increased the prices for these products in South Africa beyond the allowable SEP increases as gazetted by the South African Department of Health from time to time. Aspen hopes to demonstrate, through its active engagement with the Commission and other affected stakeholders, its ongoing commitment to supplying the South African market with quality affordable medicines for which it is renowned. To provide context to shareholders it is confirmed that, while Aspen fully acknowledges the vital nature of the four oncology products listed in the Commission’s announcement, these products have a collective turnover of about R3 million in the South African private market. Durban 14 June 2017 Sponsor: Investec Bank Limited Date: 14/06/2017 11:05:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.